Form 4: Galectin Therapeutics CEO Sells Shares

Galectin Therapeutics President and CEO Joel Lewis exercised options and sold 14,000 shares under a Rule 10b5-1 plan.

Summary

• Joel Lewis, President and CEO, Director, and 10% Owner of Galectin Therapeutics Inc. (GALT), reported transactions on September 12, 2025.
• Lewis exercised options to acquire 14,000 shares of common stock at an exercise price of $2.39 per share.
• Concurrently, Lewis sold 14,000 shares of common stock at a weighted average price of $6.3606 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on April 17, 2025, as previously disclosed in the Issuer's Quarterly Report on Form 10-Q filed on August 14, 2025.
• Following these transactions, Lewis directly beneficially owns 832,592 shares of common stock.
• Lewis also indirectly holds 2,000 shares as a USTA custodian for a minor child, for which beneficial ownership is disclaimed.
• The stock options exercised vested 100% on December 14, 2018, and are set to expire on December 14, 2027.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale reduces direct ownership, it was executed under a pre-arranged Rule 10b5-1 plan, indicating a planned liquidity event rather than a reaction to negative news. The sale was also at a significantly higher price than the option exercise price, reflecting a profitable transaction for the insider.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned sale rather than an immediate reaction to new, undisclosed information.
• The sale price of $6.3606 per share is significantly higher than the exercise price of $2.39, indicating a profitable transaction for the insider.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.

Future Outlook

N/A

Management Comments

• The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
• The shares were sold in multiple transactions at prices ranging from $6.331 to $6.51. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
• The Reporting Person disclaims beneficial ownership of these securities [held as custodian], and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.

Industry Context

This filing reports an insider transaction for Galectin Therapeutics Inc. and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: May view the insider sale as a slight negative, though mitigated by the 10b5-1 plan. The insider still retains a significant direct stake.
• Management: Joel Lewis realized a profit from exercising options and selling shares, aligning with personal financial planning.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction under a pre-arranged Rule 10b5-1 plan. While the CEO sold shares, it was a planned liquidity event and not indicative of a sudden change in company prospects. The insider still holds a substantial number of shares. This transaction alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, as it's a planned personal financial move rather than a signal about the company's immediate future performance.

Keywords

Galectin Therapeutics, GALT, Joel Lewis, Insider Trading, Form 4, Stock Options, Rule 10b5-1, CEO, Director, Share Sale